Bosh sahifaDBV • ETR
add
DBV Technologies SA
Yopilish kursi
2,29 €
Yillik diapazon
1,50 € - 2,91 €
Bozor kapitalizatsiyasi
438,34 mln EUR
Oʻrtacha hajm
1,20 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
EPA
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 2,77 mln | 158,77% |
Joriy xarajat | 37,05 mln | 18,00% |
Sof foyda | -33,16 mln | -8,94% |
Sof foyda marjasi | -1,20 ming | 57,90% |
Har bir ulushga tushum | -0,21 | 86,19% |
EBITDA | -33,49 mln | — |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 69,84 mln | 50,38% |
Jami aktivlari | 110,50 mln | 18,74% |
Jami passivlari | 57,64 mln | 47,72% |
Umumiy kapital | 52,85 mln | — |
Tarqatilgan aksiyalar | 168,95 mln | — |
Narxi/balansdagi bahosi | 5,86 | — |
Aktivlardan daromad | -67,50% | — |
Kapitaldan daromad | -110,96% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -33,16 mln | -8,94% |
Operatsiyalardan naqd pul | -32,44 mln | -44,43% |
Sarmoyadan naqd pul | -241,00 ming | -121,10% |
Moliyadan naqd pul | 130,00 ming | 1 757,14% |
Naqd pulning sof oʻzgarishi | -33,37 mln | -68,79% |
Boʻsh pul | -21,19 mln | -62,74% |
Haqida
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
Tashkil etilgan
29-mar, 2002
Xodimlar soni
117
